


# PRODUCT INFORMATION



## UK 122 (trifluoroacetate salt)

Item No. 9001218

**CAS Registry No.:** 1186653-73-5  
**Formal Name:** 4-[(E)-(5-oxo-2-phenyl-4(5H)-oxazolylidene)methyl]-benzenecarboximidamide, 2,2,2-trifluoroacetate  
**MF:** C<sub>17</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> • CF<sub>3</sub>COOH  
**FW:** 405.3  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

UK 122 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the UK 122 (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. UK 122 (trifluoroacetate salt) is soluble in acetonitrile and methanol.

### Description

UK 122 is an inhibitor of urokinase-type plasminogen activator (uPA; IC<sub>50</sub> = 0.2 μM).<sup>1</sup> It is selective for uPA over tissue-type plasminogen activator (tPA), trypsin, plasmin, and thrombin (IC<sub>50</sub>s = >100 μM for all). UK 122 (100 μM) inhibits the migration and invasion of CFPAC-1 pancreatic cancer cells. It prevents glutamate-induced phase shifts in isolated suprachiasmatic nucleus slices from tPA<sup>-/-</sup> but not wild-type mice when used at a concentration of 0.2 μM.<sup>2</sup> UK 122 (4 mg/kg) decreases disease severity and colorectal levels of RANTES in a mouse model of colitis induced by dextran sulfate (DSS; Item No. 23250).<sup>3</sup>

### References

1. Zhu, M., Gokhale, V.M., Szabo, L., *et al.* Identification of a novel inhibitor of urokinase-type plasminogen activator. *Mol. Cancer Ther.* **6(4)**, 1348-1356 (2007).
2. Cooper, J.M., Rastogi, A., Krizo, J.A., *et al.* Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice. *Eur. J. Neurosci.* **45(6)**, 805-815 (2017).
3. Kida, Y., Okahisa, T., Sato, Y., *et al.* Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice. *Sci. Rep.* **13(1)**, 2899 (2023).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM